3 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 117 points (-0.7%) at 16,295 as of Monday, April 7, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 843 issues advancing vs. 2,136 declining with 146 unchanged.

The Drugs industry currently sits down 1.4% versus the S&P 500, which is down 0.8%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 3.5%, Actavis ( ACT), down 2.4%, Allergan ( AGN), down 2.2%, Forest Laboratories ( FRX), down 1.7% and AstraZeneca ( AZN), down 0.8%. Top gainers within the industry include Questcor Pharmaceuticals ( QCOR), up 15.4%, Biogen Idec ( BIIB), up 1.5% and Eli Lilly and Company ( LLY), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Amgen ( AMGN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Amgen is down $0.64 (-0.5%) to $118.47 on average volume. Thus far, 2.4 million shares of Amgen exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $116.56-$119.74 after having opened the day at $118.19 as compared to the previous trading day's close of $119.11.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $93.7 billion and is part of the health care sector. Shares are up 4.4% year-to-date as of the close of trading on Friday. Currently there are 7 analysts that rate Amgen a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Merck ( MRK) is down $0.48 (-0.9%) to $55.64 on light volume. Thus far, 4.0 million shares of Merck exchanged hands as compared to its average daily volume of 12.9 million shares. The stock has ranged in price between $55.03-$56.16 after having opened the day at $55.37 as compared to the previous trading day's close of $56.12.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $165.3 billion and is part of the health care sector. Shares are up 12.1% year-to-date as of the close of trading on Friday. Currently there are 7 analysts that rate Merck a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.92 (-2.9%) to $31.24 on heavy volume. Thus far, 27.3 million shares of Pfizer exchanged hands as compared to its average daily volume of 27.2 million shares. The stock has ranged in price between $31.14-$31.71 after having opened the day at $31.48 as compared to the previous trading day's close of $32.16.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. Pfizer has a market cap of $207.2 billion and is part of the health care sector. Shares are up 5.0% year-to-date as of the close of trading on Friday. Currently there are 8 analysts that rate Pfizer a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

The Shifting Price Action Continued Today

The Shifting Price Action Continued Today

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

Get Ready for Volatility Now: Cramer's 'Mad Money' Recap (Monday 1/29/18)

Get Ready for Volatility Now: Cramer's 'Mad Money' Recap (Monday 1/29/18)